Valuable experiences from Feasability study with MD100 Strokefinder in emergency department in Athens

Since March 2023, a feasability study is in progress at the hospitals of Nikaia and Agia Olga in Athens. The purpose of the study is to evaluate the usability and potential value of the MD100 Strokefinder in the local emergency care environment.
Results from Nikaia were presented at the 1st Panhellenic Symposium of EEC held 15/6–18/6 in Larissa. Medfield participated together with the Greek distributor Flexmed Innovations and Technologies IKE and the study results were presented by the principal investigator Dr Dimitrios Tsiftsis, physician at Nikaia General Hospital.
During the period March-April, MD100 Strokefinder was evaluated on 57 patients in the emergency department. Within the framework of the user study, the results of the measurement were not considered and the patient was treated according to normal clinical practice.
Point-of-care unit, Strokefinder, is defined and used as a point-of-care unit, i.e. it is perceived as portable – easy to move and use where it is needed, regardless of the type of bed or stretcher, compact, with good battery life and solid construction.
Easy to use, it was found that the instrument can be used by most categories of healthcare professionals after a short user training, with very low frequency of incorrect use or error messages and that the patients had high acceptance of the instrument and measurement.
Effect in the care pathway, the use of Strokefinder was not found to have negative effects on the time to radiological examination of the patient and had minimal
effect on door-to-triage time. Nor were any negative time effects found in the rest of the acute triage flow.
Some additional observations were also reported; Certain body types and anatomies can pose challenges when fitting into the instrument. Patients with stabilized neck can also lead to difficulties in using the instrument.
With the assessment that MD100 Strokefinder has high usability and can add value to their environment, the intention is now to evaluate the sensitivity and specificity of the use of MD100 Strokefinder in clinical practice.
“It is very gratifying that the staff at the emergency departments at these hospitals are so positive about using the MD100 Strokefinder. It confirms the company’s assessment that there is great interest in MD100 Strokefinder from this customer group”, says Jonas Liljedal, Director Sales & Marketing Medfield Diagnostics AB (publ)
For more information, please contact:
Stefan Blomsterberg, CEO, Medfield Diagnostics AB, Tel:+4631160668,
Medfield Diagnostics aims to facilitate the diagnosis of stroke and head trauma. If it can be determined at an early stage whether the patient has a stroke or not, the treatment process could be accelerated and the right treatment started much earlier than today. In this way, a lot of suffering can be eliminated for affected patients and very large care and rehabilitation costs for society could be saved.